Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Cash from Financing Activities data on file, last reported at $66.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $66.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $66.4 million (down 61.62% YoY), and the FY2025 annual result was -$288000.0, down 100.16% from the prior year.
• Cash from Financing Activities improved to $66.6 million in Q1 2026 per PHAT's latest filing, from -$97000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $212.0 million in Q4 2023 and troughed at -$271000.0 in Q3 2025.
• A 5-year average of $49.3 million and a median of $24.6 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 938800.0% in 2024, then slumped 100.37% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $24.6 million in 2022, then jumped by 761.9% to $212.0 million in 2023, then sank by 87.71% to $26.0 million in 2024, then tumbled by 100.37% to -$97000.0 in 2025, then surged by 68801.03% to $66.6 million in 2026.
• Business Quant data shows PHAT's Cash from Financing Activities at $66.6 million in Q1 2026, -$97000.0 in Q4 2025, and -$271000.0 in Q3 2025.